Searchable abstracts of presentations at key conferences in endocrinology

ea0063p247 | Pituitary and Neuroendocrinology 1 | ECE2019

MRI follow-up is not useful in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogs (SMSa)

Grandgeorge Naia , Barchetti Giovanni , Grunenwald Solange , Bonneville Fabrice , Caron Philippe

Introduction: Primary SMSa treatment can be associated with hormonal remission and tumor shrinkage in patients with GH-secreting pituitary adenomas. In the 2014 Endocrine Society guideline for Acromegaly, there is no specific mention of MRI follow-up during long-term SMSa treatment. The aim of this study was to evaluate any change of GH-secreting adenoma size during primary SMSa treatment and whether regular MRI follow-up was necessary in acromegalic patients treated with firs...

ea0070aep759 | Pituitary and Neuroendocrinology | ECE2020

MRI follow-up of patients with acromegaly treated with first-generation somatostatin analogues (SMSa): Is there a difference during primary or post-operative treatment?

Naia Grandgeorge , Giovanni Barchetti , Solange Grunenwald , Fabrice Bonneville , Caron Philippe

Objectives: First-generation SMSa are the medical treatment of choice in the management of acromegaly, mainly as adjuvant treatment of pituitary surgery when normal IGF-1 is not obtained or as primary treatment in selected patients. The main objective of this study is to evaluate regular pituitary MRI follow-up of acromegalic patients treated with SMSa as adjuvant treatment of pituitary surgery. The secondary objective is to compare the anti-tumoral effect of SMSa in post-oper...

ea0041gp161 | Pituitary - Clinical (1) | ECE2016

Evaluation of MRI T2-signal intensities of GH-secreting pituitary macroadenoma in treatment-naïve acromegalic patients receiving primary treatment with lanreotide autogel (LAN-ATG) 120 mg

Caron Philippe , Riviere Louis-David , Houchard Aude , Sert Caroline , Bonneville Fabrice

Introduction: Pituitary MRI T2-signal intensity may be associated with the response to somatostatin analogue therapy in acromegalic patients. Here, we explore how best to evaluate MRI T2-signal intensity of GH-secreting pituitary macroadenoma using data from the PRIMARYS study (NCT00690898; EudraCT2007-000155-34).Methods: PRIMARYS assessed tumour volume reduction (TVR) on MRI in treatment-naïve acromegalic patients with GH-secreting pituitary macroa...

ea0081p159 | Pituitary and Neuroendocrinology | ECE2022

What is the relevance of he systematic use of gadolinium (Gd) during the MRI follow-up of non-functioning pituitary adenomas (NFPAs)?

Villemaire Axel , Mouly Celine , Solange Grunenwald , Adam Gilles , Darcourt Jean , Patsoura Sofia , Roques Margaux , Catalaa Isabelle , Fayolle Helio , Cognard Christophe , Sol Jean-Christophe , Caron Philippe , Fabrice Bonneville

Objective: To compare the performances of the coronal contrast-enhanced T1-weighted (ceT1-w) and T2-weighted (T2-w) sequences, for the diagnosis of progression during the MRI follow-up of NFPAs.Materials and methods: 106 patients who had at least two MRIs for the follow-up of NFPA were retrospectively included. The largest diameter of the adenomas was measured on coronal ceT1-w and separately on T2-w sequences for all the MRIs of the follow-up, and by 2 ...